

Name	Mrs.VAIJAYANTHI A	ID	MED111466557
Age & Gender	51/FEMALE	Visit Date	28/01/2023
Ref Doctor Name	MediWheel		

### **MAMMOGRAPHY**

#### REPORT

Cranio-caudal and Medio-lateral oblique views of both breasts were studied.

Both breasts are fatty with fibroglandular densities (ACR Type B parenchyma).

A small, round, high density lesion, measuring  $\sim 5.3 \times 4.5$  mm is noted in the upper outer quadrant, posterior portion of the right breast.

Few benign amorphous microcalcification is noted in anterior portion of both breasts.

No breast asymmetry noted.

No intramammary ductal dilatation identified.

No obvious spiculation or architectural distortion noted.

Both nipples are not retracted.

There is no evidence of focal or diffuse thickening of skin or subcutaneous tissue of both breasts.

The retro-mammary spaces appear normal.

Left axilla shows an enlarged lymph node, measuring 13 mm, with preserved fatty hilum.

### **IMPRESSION:**

- ACR Type B parenchyma.
- Right breast lesion as described above- BIRADS II
- Left Axillary lymphadenopathy.
  - Suggested USG/ FNAC Correlation.
  - Suggested Annual Review Scans- ACR guidelines.



# Dr Sharanya.S MD, DNB Radiologist

#### REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3.Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- 11. Disputes, if any, with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.



Name	Mrs.VAIJAYANTHI A	ID	MED111466557
Age & Gender	51/FEMALE	Visit Date	28/01/2023
Ref Doctor Name	MediWheel		

Category - (BIRADS classification)

Category 0: Assessment incomplete. Category 1: Negative (normal).

Category 2: Benign. Category 3: Probably benign finding.

Category 4: Suspicious abnormality. Category 4a: Low suspicion 4b - Intermediate suspicion.

Category 4c: Moderate suspicion. Category 5: High suggestive of malignancy.

Category 6: Known biopsy proven malignancy.

NOTE: Please bring your old mammogram film for the next visit.

#### REPORT DISCLAIMER

<sup>1.</sup>This is only a radiological imperssion.Like other investigations, radiological investication also have limitation. Therefore radiological reports should be interpreted in correlation with clinical and pathological findings.

<sup>2.</sup> The results reported here in are subject to interpretation by qualified medical professionals only.

<sup>3.</sup>Customer identities are accepted provided by the customer or their representative.

<sup>4.</sup>information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.

<sup>5.</sup>If any specimen/sample is received from any others laboratory/hospital,its is presumed that the sample belongs to the patient identified or named.

<sup>6.</sup>Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.

<sup>7.</sup>Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,

<sup>8.</sup>If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.

<sup>9.</sup>Liability is limited to the extend of amount billed.

<sup>10.</sup>Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.

<sup>11.</sup>Disputes,if any , with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

Type : OP Printed On


Ref. Dr : MediWheel



: 03/02/2023 6:08 PM

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
BLOOD GROUPING AND Rh TYPING	'AB' 'Positive'		
(EDTA Blood/Agglutination)			
INTERPRETATION: Reconfirm the Blood grou	p and Typing before	blood transfusion	
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	12.7	g/dL	12.5 - 16.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood/Derived from Impedance)	39.8	%	37 - 47
RBC Count (EDTA Blood/Impedance Variation)	4.81	mill/cu.mm	4.2 - 5.4
Mean Corpuscular Volume(MCV) (EDTA Blood/Derived from Impedance)	82.7	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood/Derived from Impedance)	26.3	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood/Derived from Impedance)	31.8	g/dL	32 - 36
RDW-CV (EDTA Blood/Derived from Impedance)	14.2	%	11.5 - 16.0
RDW-SD (EDTA Blood/Derived from Impedance)	41.10	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood/Impedance Variation)	8520	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood/Impedance Variation & Flow Cytometry)	55.9	%	40 - 75
Lymphocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	33.7	%	20 - 45
Eosinophils (EDTA Blood/Impedance Variation & Flow Cytometry)	4.0	%	01 - 06





**APPROVED BY** 

The results pertain to sample tested.

Page 1 of 7

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

 Age / Sex
 : 51 Year(s) / Female
 Report On
 : 30/01/2023 9:36 PM

**Printed On** 



Type : OP

Ref. Dr : MediWheel

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	6.1	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.3	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results a	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA BloodImpedance Variation & Flow Cytometry)	4.76	10^3 / μl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.87	10^3 / μΙ	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.34	10^3 / μl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.52	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.03	10^3 / μl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	290	10^3 / μl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	11.2	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.32	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	36	mm/hr	< 30
BUN / Creatinine Ratio	10.8		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	107.6	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125

: 03/02/2023 6:08 PM





Diabetic:  $\geq$  126

**APPROVED BY** 

The results pertain to sample tested.

Page 2 of 7

: MediWheel

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

 Age / Sex
 : 51 Year(s) / Female
 Report On
 : 30/01/2023 9:36 PM

**Printed On** 



Type : OP

Ref. Dr

<u>Investigation</u>	<u>Observed</u> <u>l</u>	<u>Jnit</u>	<u>Biological</u>
	Value		Reference Interval

**INTERPRETATION:** Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

: 03/02/2023 6:08 PM

Glucose, Fasting (Urine)	Negative		Negative
(Urine - F/GOD - POD)			
Glucose Postprandial (PPBS)	104.1	mg/dL	70 - 140

(Plasma - PP/GOD-PAP)

#### INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

### Remark: Please correlate clinically.

Urine Glucose(PP-2 hours)	Negative		Negative
(Urine - PP)			
Blood Urea Nitrogen (BUN) (Serum/ <i>Urease UV / derived</i> )	7.6	mg/dL	7.0 - 21
Creatinine (Serum/Modified Jaffe)	0.70	mg/dL	0.6 - 1.1

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin, cefazolin, ACE inhibitors, angiotensin II receptor antagonists, N-acetylcysteine, chemotherapeutic agent such as flucytosine etc.

Uric Acid (Serum/Enzymatic)	3.4	mg/dL	2.6 - 6.0
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.26	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.10	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.16	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase)	20.9	U/L	5 - 40



(Serum/Modified IFCC)



APPROVED BY

The results pertain to sample tested.

Page 3 of 7

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

**Age / Sex**: 51 Year(s) / Female **Report On**: 30/01/2023 9:36 PM

**Printed On** 

Type : OP

Ref. Dr : MediWheel



<u>Investigation</u>	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
SGPT/ALT (Alanine Aminotransferase) (Serum/ <i>Modified IFCC</i> )	29.7	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	21.1	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/ <i>Modified IFCC</i> )	113.5	U/L	53 - 141
Total Protein (Serum/ <i>Biuret</i> )	7.59	gm/dl	6.0 - 8.0
Albumin (Serum/ <i>Bromocresol green</i> )	4.35	gm/dl	3.5 - 5.2
Globulin (Serum/ <i>Derived</i> )	3.24	gm/dL	2.3 - 3.6
A : G RATIO (Serum/ <i>Derived</i> )	1.34		1.1 - 2.2
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	212.4	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	82.8	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

: 03/02/2023 6:08 PM

**INTERPRETATION:** The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the `usual\_circulating level of triglycerides during most part of the day.

HDL Cholesterol 64.1 mg/dL Optimal(Negative Risk Factor): >=

(Serum/Immunoinhibition)

60 Borderline: 50 - 59 High Risk: < 50





**APPROVED BY** 

Age / Sex : 51 Year(s) / Female

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

Report On

MEDALI

Type : OP Printed On : 03/02/2023 6:08 PM

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
LDL Cholesterol (Serum/Calculated)	131.7	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	16.6	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	148.3	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

: 30/01/2023 9:36 PM

**INTERPRETATION:** 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio (Serum/Calculated)	3.3		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	1.3		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2.1		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/ <i>HPLC</i> )	6.4	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %





**APPROVED BY** 

The results pertain to sample tested.

Page 5 of 7


PID No. : MED111466557 **Register On** : 28/01/2023 7:55 AM : 223001331 SID No. Collection On : 28/01/2023 9:34 AM

Age / Sex : 51 Year(s) / Female Report On : 30/01/2023 9:36 PM

**Type** : OP **Printed On** : 03/02/2023 6:08 PM

Ref. Dr : MediWheel

(Whole Blood)



### **INTERPRETATION: Comments**

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

### THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total	1.10	ng/ml	0.4 - 1.81
(Serum/Chemiluminescent Immunometric Assay			

(CLIA))

#### INTERPRETATION:

#### **Comment:**

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

4.2 - 12.0T4 (Tyroxine) - Total 10.21 µg/dl

(Serum/Chemiluminescent Immunometric Assay

(CLIA))

### INTERPRETATION:

#### Comment ·

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 2.74 μIU/mL 0.35 - 5.50

(Serum/Chemiluminescent Immunometric Assay

(CLIA))

### **INTERPRETATION:**

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester: 0.3-3.0

(Indian Thyroid Society Guidelines)


### **Comment:**

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.

2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%,hence time of the day has influence on the measured serum TSH concentrations.

3. Values & amplt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.





**APPROVED BY** 

The results pertain to sample tested.

Page 6 of 7

Lab Address: MEDALL HEALTHCARE PRIVATE LIMITED,#17,RACE VIEW COLONY, 2ND STREET, RACE COURSE ROAD, GUINDY, CHENNAI, TAMIL NADU, INDIA.,

 PID No.
 : MED111466557
 Register On
 : 28/01/2023 7:55 AM

 SID No.
 : 223001331
 Collection On
 : 28/01/2023 9:34 AM

 Age / Sex
 : 51 Year(s) / Female
 Report On
 : 30/01/2023 9:36 PM

**Printed On** 



Type : OP

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
<u>Urine Analysis - Routine</u>			
COLOUR (Urine)	Pale yellow		Yellow to Amber
APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Negative		Negative
Pus Cells (Urine/Automated Flow cytometry)	Occasional	/hpf	NIL
Epithelial Cells (Urine/Automated Flow cytometry)	Occasional	/hpf	NIL
RBCs (Urine/Automated Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated Flow cytometry)	NIL	/hpf	NIL
Others (Urine)	NIL		

: 03/02/2023 6:08 PM

**INTERPRETATION:** Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.





**APPROVED BY** 

-- End of Report --

Name : Mrs. VAIJAYANTHI A Register On : 28/01/2023 7:55 AM



SID No. : 223001331 Report On : 30/01/2023 9:36 PM

Age / Sex : 51 Year(s) / Female Printed On : 03/02/2023 6:08 PM

Ref. Dr : MediWheel OP / IP : OP

# PAP Smear by LBC( Liquid based Cytology )

**SPECIMEN NO:** Cy 214/2023

**MICROSCOPIC FINDINGS:** 

**ADEQUACY:** Satisfactory.

**PREDOMINANT CELLS:** Superficial and intermediate cells.

**BACKGROUND:** A few neutrophils.

**ORGANISMS:** No specific organisms.

## **IMPRESSION:**

Negative for intraepithelial lesion/ malignancy.



APPROVED BY

-- End of Report --